Ramsay Générale de Santé (GDS) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
3 Jul, 2026Strategic and operational highlights
Maintained leading position in France, Sweden, Norway, and Denmark, operating 492 healthcare facilities and serving over 12 million patients in 2025.
Achieved record patient satisfaction with a net promoter score of 74% and renewed key hospital management contracts.
Integrated COSEM primary care centers, enhancing care pathways and realizing operational synergies.
Continued expansion in primary care, mental health, and imaging, with 10 new facilities and six new day hospitals opened.
Invested €136 million in CapEx, focusing on modernization and quality improvements.
Financial performance and outlook
Revenue grew 4.7% to €5.2 billion, with France up 5.9% and Nordic countries up 2.2%.
EBITDA reached €621 million (11.9% margin), but net income remained negative at -€54.1 million due to high financial costs.
Operating cash flow increased to €694 million, and financial leverage improved to 4.7x.
Successfully refinanced senior debt, extending maturity to 2031 and securing better terms.
Share performance remained weak amid challenging economic and political conditions in France.
ESG and mission-driven initiatives
Achieved 31% reduction in carbon footprint and 94% hospital certification rate.
Over 60% of hospitals located in underserved areas, improving healthcare access.
Supported over 100 startups and associations for preventative health actions.
Published first CSRD report, with external assurance confirming compliance and no significant errors.
Mission Committee highlighted strong progress in embedding mission objectives and environmental maturity.
Latest events from Ramsay Générale de Santé
- Revenue up 6.5%, but net loss of €53.9M as margins fell and costs rose; refinancing completed.GDS
H2 20231 Jul 2026 - Revenue and EBITDA rose strongly, with key contract wins and acquisitions driving growth.GDS
Q1 20241 Jul 2026 - Revenue up 5.8% to €2.5B, EBITDA stable, net loss widens on higher costs and debt.GDS
H1 20241 Jul 2026 - Revenue up 5.1% to €3.89bn, EBITDA stable, France drives growth, debt repriced for 2031.GDS
Q3 20241 Jul 2026 - Revenue and EBITDA increased despite subsidy cuts, with stable net loss and improved leverage.GDS
H2 20241 Jul 2026 - Revenue and EBITDA grew despite funding constraints, but net debt rose to €3.82 billion.GDS
Q1 20251 Jul 2026 - Revenue and EBITDA rose, net loss narrowed, and leverage improved amid funding pressures.GDS
Q3 20251 Jul 2026 - Revenue up 3.3% to €2.59B, EBITDA stable, net loss narrows, leverage improves.GDS
H1 20251 Jul 2026